Introduction
Telomere dysfunction and telomerase activation play paradoxical roles in tumorigenesis. It has been argued that telomere shortening in human somatic cells where telomerase is absent suppresses tumor formation by limiting the number of times that cells can divide . However, telomere shortening has been shown to increase genetic instability and tumor formation in mice (Blasco et al., 1997; Rudolph et al., 1999) . Telomerase activation in cancer adds another level of complexity. Telomerase is activated in 90% of tumors and this activation is thought to confer immortal growth properties on the tumor cells (Kim et al., 1994; Shay and Bacchetti, 1997) . Telomerase activation is thought to occur late in tumorigenesis (Chadeneau et al., 1995; Tang et al., 1998) . In contrast, chromosomal instability is thought to be initiated early in tumorigenesis (Shih et al., 2001) . It has been argued that telomerase activation occurs after the initiation of genetic instability and is necessary to inhibit further instability by stabilizing chromosome ends (DePinho, 2000; Rudolph et al., 2001) . However, it is unclear whether telomerase activation in tumors facilitates tumor growth by circumventing checkpoints that recognize dysfunctional telomeres or by stabilizing chromosome rearrangements. Therefore, telomere shortening and telomerase activation appear to have both tumor suppressive and oncogenic roles: the apparent tumor suppressive role of telomere shortening may help to initiate genetic instability, and the apparent oncogenic role of telomerase activation may help to stabilize genetic instability ( Figure 1) . De®ning under what circumstances each of these mechanisms operate is essential to an understanding of the complex roles of telomeres and telomerase in cancer.
Telomeres are protected from being recognized by the cell as a DNA break Hermann J Muller was the ®rst to begin to de®ne the specialized functions of telomeres. While irradiating Drosophila with X-rays to produce mutations, Muller noticed that the ends of the chromosomes had properties that distinguished them from the ends of the chromosome fragments produced by radiation (Muller, 1938) . While ends produced by irradiation could be rejoined with other broken ends to produce chromosomal rearrangements, the natural ends of the chromosomes were not fused to other ends. Muller proposed that the telomeres have the special property of sealing the ends of chromosomes. This characterization of telomere function was augmented by the work of Barbara McClintock (McClintock, 1941) . She engineered the formation of dicentric chromosomes in maize by allowing rearranged chromosomes to recombine during meiosis. She demonstrated that the force of the movement of the two centromeres to opposite spindle poles during cell division broke the dicentric chromosome at a variable location. In addition she showed that the broken chromosome ends in the daughter cells could fuse with the ends of their broken sister chromatids prior to mitosis. Fusion of these broken DNA ends propagated a breakage-fusionbridge (BFB) cycle that resulted in either gene deletion or gene ampli®cation. She proposed that telomeres protected natural DNA ends from chromosome fusion. Therefore, Muller and McClintock de®ned the ends of linear chromosomes as structures that are distinct from DNA breaks and provide protection from processes that fuse broken chromosomes.
Telomeres are composed of repetitive TG-rich sequences and the proteins that bind them. S cerevisiae telomere sequence contain *300 base pairs of an irregular TG 1 ± 3 repeats (Zakian, 1989) . Mammalian telomeres are much longer, *40 kb in inbred strains of mice and 10 ± 15 kb of TTAGGG repeats in humans. Telomeres are elongated by the ribonucleoprotein enzyme telomerase that contains essential reverse transcriptase and RNA template components (Greider and Blackburn, 1989) . Telomere shortening occurs in the absence of telomerase and results in loss of telomere function, as described below.
In addition to telomere length, telomere function is conferred by proteins that bind telomeric DNA (reviewed in Gasser, 2000) . Loss of protein binding at telomeres causes end-to-end chromosome fusions. In yeast, Rap1 binds along the length of telomeric DNA and acts as a negative regulator of telomere length (Conrad et al., 1990; Lustig et al., 1990) . Mutating the Rap1 binding site in K lactis through telomerase RNA template mutations can cause either telomere shortening or telomere elongation, depending on the speci®c mutation. Both types of mutants show chromosome circularization with retention of telomere sequence at the junction (McEachern et al., 2000) . In similar experiments, telomerase RNA template mutations have been introduced into human cells. Cells expressing mutant telomerase RNA have a reduced growth rate, reduced viability, and an abnormal cell cycle (Guiducci et al., 2001) . The cells also have abnormal nuclei and large numbers of chromosome fusions. These fusions retain telomere sequence at the junction. Expression of a mutant template alters the binding sites for telomere binding proteins that maintain telomere function; loss of this binding results in loss of telomere function and chromosome fusion.
In addition to the general deregulation of telomere function observed when mutant RNA templates are expressed, the loss of several speci®c telomere-binding proteins can alter telomere structure and cause chromosome fusions. The ciliates Oxytrichia and Euplotes have a telomere end-binding protein, the ab heterodimer, that caps the ends of their telomeres, preventing degradation (Gray et al., 1991; Hicke et al., 1990; Wang et al., 1992) . A homologue of the a subunit, Pot1, was recently identi®ed in S pombe and humans and was shown to bind G-strand telomeric DNA (Baumann and Cech, 2001) . In S pombe, Pot1 + de®ciency causes rapid loss of telomere sequence and chromosome circularization. Pot1 is proposed to function as a cap at the end of linear chromosomes in yeast and humans that is essential for the maintenance chromosome integrity.
A specialized telomere structure, the t-loop, has also been implicated in the maintenance of telomere function in humans (Grith et al., 1999) . In a t-loop, the single stranded G-tail of the telomere loops around and base pairs with a more proximal region of telomeric DNA, causing displacement of one strand. TRF2 localizes to this displacement loop and has been proposed to be necessary for establishing or maintaining t-loop structure in conjunction with the Mre11/ Rad50/Nbs1 complex (Zhu et al., 2000) . Consistent with TRF2 playing a role in t-loop and telomere function, expression of a dominant negative TRF2 protein in human cells results in loss of TRF2 binding Figure 1 Dual roles for telomerase and telomere dysfunction in genetic instability and tumor growth. Telomere shortening can potentially contribute to the genetic instability that drives tumorigenesis. Early stage tumors with ongoing genetic instability are represented by the cluster of multicolored balls. However, telomere shortening may also limit tumor growth by activating checkpoints. Telomerase activation can facilitate tumor growth, but telomerase can also help to control genetic instability. Late stage tumors in which certain cells have been selected from early stages in tumor progression are represented by the large cluster of blue and purple balls to telomeres and loss of G-strand overhangs and an increase in the number of anaphase bridges and chromosome fusions. These fusions often have telomere sequence at the junction (van Steensel et al., 1998) . Finally the dominant negative TRF2 protein induces an increase in apoptosis mediated by ATM and p53, consistent with loss of TRF2 binding making telomeres resemble a double strand break (Karlseder et al., 1999) .
Telomere shortening increases genetic instability
Telomere shortening is associated with an increased tumor formation rate in the telomerase knockout (mTR 7/7 ) mouse. There is a 4 ± 6-fold increase in spontaneous tumor incidence in late generation mTR 7/7 mice that have short telomeres and the age of tumor onset is younger than wildtype (Rudolph et al., 1999) . Tumors arise from highly proliferative tissues that may have particularly short telomeres due to the large number of cell divisions. A possible explanation for this increase in tumor formation is the increase in genetic instability that occurs in late generation mTR 7/7 mice. mTR 7/7 cells have increased frequencies of signal-free ends (telomeres without detectable telomere repeats by FISH) and end-to-end chromosome fusions (Blasco et al., 1997; Hemann et al., 2001) . Chromosome ends that most frequently lack a FISH signal preferentially participate in end-to-end fusions, thus providing a direct link between short telomeres and end-to-end fusions (Hemann et al., 2001) . Signi®cantly, mTR 7/7 tumors have a 3 ± 18-fold increase in chromosome fusions and a twofold increase in aneuploidy compared to mTR +/+ tumors (Rudolph et al., 1999) . Therefore, chromosomal instability might help to initiate tumorigenesis in mTR 7/7 mice. In support of this hypothesis, p53 de®ciency increases the frequency of chromosome fusions and aneuploidy and decreases apoptosis in late generation mTR 7/7 cells . Moreover, reintroduction of mTR on a vector in G6 mTR 7/7 p53 7/7 cells inhibits their ability to form foci in a Myc/RAS transformation assay . Introduction of mTR has no eect in an mTR +/+ background. This suggests that telomere dysfunction cooperates with p53 de®ciency to initiate malignant transformation. Telomere dysfunction in late generation mTR 7/7 mice also results in tumor formation at an earlier age in a p53 7/7 or p53 +/7 background (Artandi et al., 2000) . Direct evidence that telomere shortening can cause genomic instability comes from the study of S cerevisiae. est1D yeast exhibit progressive telomere shortening accompanied by a loss of growth rate after a lag period (Lundblad and Szostak, 1989) . The measurement of the rate of loss of a marker gene in haploid est1D yeast revealed an increase in mutation rate as telomeres shortened (Hackett et al., 2001) . This increase in mutation rate resulted from an increased frequency of terminal, but not internal deletions. The broken chromosome ends could initiate nonreciprocal, but not reciprocal translocations. The presence of nonreciprocal translocations and the fact that internal deletions did not increase suggest that speci®cally the distal portion of the chromosome with telomere dysfunction is lost. This might be caused either by resection of terminal DNA or by end-to-end chromosome fusions and breakage during mitosis. Importantly, the production of a broken chromosome with the loss of distal sequence is mutagenic. If the cell does not die, the single broken end can lead to chromosome loss or it can initiate a nonreciprocal translocation, or possibly fuse to another dysfunctional telomere, creating a new dicentric chromosome. The least mutagenic outcome in a haploid is de novo addition of telomere repeats onto the broken end, a process that requires telomerase (Kramer and Haber, 1993) . In diploid cells, a broken chromosome can also be repaired by the copying of the DNA from its homologue, another potential mechanism for loss of heterozygosity (Bosco and Haber, 1998; Malkova et al., 1996) .
In est1D yeast, the increase in terminal deletions was inversely proportional to the decrease in growth rate due to telomere dysfunction (Hackett et al., 2001) . To measure the mutation rate in cultures where telomere shortening decreases growth rate and colony formation, telomerase was reactivated when cells were plated. This reactivation prevented a decrease in colony number and size. Because mutants were selected based on resistance to a toxic drug, marker loss would have to occur before plating the cells. This suggests that, at least in yeast, the decrease in cell growth due to telomere dysfunction does not completely prevent the initiation of chromosomal instability. The initial chromosomal instability may have occurred in cells that were still dividing, or in cells that`repaired' dysfunctional telomeres through end-to-end fusion, or other mechanisms. Similarly, an induced chromosome break can persist in a yeast colony for a number of cell divisions before arrest or chromosome loss occurs (Sandell and Zakian, 1993) .
A precedent for chromosome fusion in cells with dysfunctional telomeres is found in S pombe. Strains with progressive telomere shortening due to loss of telomerase reverse transcriptase (trt + ) or both ATM homologues (tel1 + and rad3 + ) exhibit a progressive loss of growth rate until survivors emerge that have circularized all three chromosomes (Naito et al., 1998; Nakamura et al., 1998) . Therefore, telomere dysfunction in S pombe or S cerevisiae can initiate chromosomal instability in the presence of functional DNA damage checkpoints. However, this situation in yeast may not occur in mammalian cells where more stringent responses to dysfunctional telomeres may exist.
How does telomere dysfunction lead to end-to-end chromosome fusions?
Because telomere function distinguishes the ends of chromosomes from DNA breaks, it would be predicted that loss of this function should allow double-strand break repair to act upon telomeres. Although a number of factors that prevent chromosome fusion have been identi®ed, the mechanism involved in fusing dysfunctional telomeres is poorly understood. Chromosome fusion junctions from cells with dysfunctional telomeres have been isolated from S cerevisiae (Hackett et al., 2001 ) and mice (Hemann et al., 2001) . The structures of these fusion junctions are strikingly similar, suggesting the possibility of a common mechanism for their formation. Fusion junctions from both organisms contain 0 ± 10 bp of microhomology, characteristic of a nonhomologous end-joining mechanism. These fusions involve the loss of all telomeric and some subtelomeric sequence, as is seen for circularized chromosomes of trt 7 or pot1 7 S pombe (Baumann and Cech, 2001; Nakamura et al., 1998) . This loss of sequence suggests that the mechanism of fusion might be an error-prone DNA repair pathway.
The role of Ku and other NHEJ proteins at telomeres (Lewis and Resnick, 2000) has been puzzling since telomeres are normally protected from endjoining. Ku binds the ends of telomeric DNA in vitro and in vivo Hsu et al., 1999) . However, several experiments suggest that Ku/ Lig4-dependent NHEJ is not essential for chromosome fusion. In S pombe, chromosome circularization in response to dysfunctional telomeres occurs in trt 7 , trt 7 pku70
7 , trt 7 lig4 7 , and trt 7 rad22 7 strains (rad22 + is the S pombe RAD52 homologue) (Baumann and Cech, 2000) . Therefore, chromosome fusion does not appear to be mediated by homologous recombination or NHEJ. Further, the rate of formation of terminal deletions in response to dysfunctional telomeres in S cerevisiae is not decreased in rad52D or lig4D backgrounds (Hackett et al., 2001) . Interestingly, in mice, deletion of the NHEJ proteins Ku, Lig4, or DNA-PK cs increases the number of telomere fusions and chromosomal rearrangements (Bailey et al., 1999; Ferguson et al., 2000; Hsu et al., 2000; Sekiguchi et al., 2001) . While it is unclear whether the telomere fusions are the result of speci®c telomere defects or general genomic instability, the fact that these fusions can occur in the absence of NHEJ proteins suggests that another mechanism is capable of fusing telomeres. There may be particular conditions, however, under which telomere fusion can be mediated by NHEJ. The chromosomes of S pombe taz1 7 mutants, which have extremely long telomeres, undergo Ku, Lig4-dependent end-to-end fusion under speci®c cell growth conditions (Ferreira and Cooper, 2001 ).
Telomere shortening inhibits tumor growth
The idea that telomere shortening may suppress the growth of tumors originated from the model of primary human cell culture. In primary cells, telomeres shorten progressively prior to senescence, when the growth of the culture declines and reaches a plateau (Figure 2a) (Harley et al., 1990) . It was proposed that telomere shortening provides a mechanism for cells to count the number of times that they have divided. If the senescence checkpoint is bypassed by transfection with SV40 T-antigen, the culture continues to grow for a limited number of cell divisions until all cells have stopped dividing at a point called crisis. Infrequently, some cells can escape from crisis and gain the ability to divide inde®nitely (immortalization) (Wright and Shay, 1992) . At crisis, there is a peak in dicentric chromosomes and telomere associations. After crisis, telomerase activity is detected, the number of dicentrics stabilized, and telomere length is stabilized after a few cell divisions at a length shorter than the initial telomere length (Counter et al., 1992; Ducray et al., 1999) .
It has been proposed that the senescence that occurs in human cell culture might parallel a similar barrier to growth as a result of short telomeres in tumorigenesis . In fact, telomeres are shorter in human tumors compared to surrounding normal tissue (de Lange et al., 1990) . Parallels have also been drawn between the increased genetic instability just prior to crisis and telomerase activation and the presence of genetic instability followed by telomerase activation in human cancer (DePinho, 2000) .
Despite the insights gained from cell culture, it has not yet been de®nitively established that telomere shortening limits the growth of human tumors or that telomere dysfunction contributes to genetic instability in human tumorigenesis. Dierences in telomere length, cell culture pro®le, and tumor spectrum in mice and humans have contributed to the continued ambiguity of the role of telomeres in human cancer. Signi®cantly, the cell culture pro®le for human primary cells is not recapitulated in mice. Primary mouse cells lack a true senescence checkpoint and immortalize spontaneously (Figure 2b ) (Todaro and Green, 1963 ). This dierence is not an eect of the much longer telomere lengths in mice compared to humans, but is likely due to the absence of a speci®c checkpoint in the mouse (Greider, 2002) . Mouse cells with very short telomeres do not undergo senescence and immortalize spontaneously with kinetics similar to wildtype cells (Blasco et al., 1997) .
The dierence between the mouse and human cell culture models may be signi®cant to the dierence in tumor pro®le in mice and humans. Adult human tumors are predominantly epithelial carcinomas while pediatric human tumors and mouse tumors are predominantly sarcomas and lymphomas (reviewed in DePinho, 2000) . DePinho has proposed that this dierence in tumor spectrum is due to dierences in telomere length and regulation in mice. Extremely long telomere lengths and somatic telomerase expression in mice would prevent dysfunctional telomeres from playing a role in tumorigenesis. In support of this argument, mice with short telomeres and p53 de®ciency develop human-like epithelial tumors (Artandi et al., 2000) . While mice with short telomeres do seem to provide better models of the early stages of human epithelial carcinomas, these mice lack the telomerase RNA, so they can never reactivate telomerase as is seen in later stages of human tumorigenesis.
Experiments mTR 7/7 mice by treatment with DMBA and UVB, short telomeres reduce the tumor incidence (Greenberg et al., 1999 mTR 7/7 mice are injected into SCID mice, there is a signi®cant reduction in the number of signal free ends and an increase in the number of fusions/metaphase in the tumor compared to the parental culture. Therefore, there is selection against signal free ends and selection for chromosome fusions in a situation where cell growth control is lost, but DNA damage recognition is intact. To assess the role of telomerase in this process, mTR is reintroduced during Myc/RAS transformation. Signi®cantly, in tumors derived from these cells, there is a reduction in signalfree ends, but no reduction in end-to-end fusions.
Similar results are obtained in human cancer cell lines in which telomerase function was suppressed by expression of a dominant negative telomerase reverse transcriptase (TERT). These cells exhibit telomere shortening and loss of growth capacity after a lag period (Hahn et al., 1999; Zhang et al., 1999) . Dominant negative TERT expression eliminates the ability of these cells to form tumors in nude mice. Therefore, short telomeres can suppress tumorigenesis.
An optimal degree of telomere dysfunction for tumorigenesis?
Insight into the relationship between genomic instability and tumor suppression in response to short telomeres comes from studies of telomere dysfunction in the Apc Min mouse (Rudolph et al., 2001) . These mice all develop multiple intestinal neoplasias and die at 4 ± 6 months of age. Apc
Min mice have deregulated cell growth due to buildup of û-catenin in the absence of APC (reviewed in Peifer and Polakis, 2000) . Apc Min cells also show increased chromosomal instability, with gross changes in ploidy and some chromosomal rearrangements (Fodde et al., 2001; Kaplan et al., 2001) . In the mTR 7/7 background used to generate Apc Min mTR 7/7 mice, generation 4 (G4) mice were the last generation of mice in the absence of telomerase that could be generated. Survival decreased in G2 and G3 Apc Min mTR 7/7 mice, however, it increased again to the wildtype level in G4 mice. This phenotype may result from increased genetic instability in G2 and later telomerase null mouse generations but poorer tumor growth in response to dysfunctional telomeres in G4.
Tumors in the Apc
Min mouse can be quantitated and microadenomas can be distinguished from the later staged macroadenomas. Microadenoma numbers peaked in G3 and was still fairly high in G4. In contrast, macroadenoma number peaked in G2 and was almost zero in G4. Additionally, macroadenoma size decreased progressively from wildtype to G4. Therefore more adenomas were initiated in G4, but fewer progressed to the macroadenoma stage. In macroadenomas, the frequency of anaphase bridges increased from wildtype to G4. All tumors were p53 positive, but macroadenomas in late generation mice showed increased p53 expression and increased apoptosis (Rudolph et al., 2001) .
The presence of p53 activity in Apc Min mTR 7/7 tumors suggests that chromosomal instability can be initiated by short telomeres in mice prior to inactivation of p53. Therefore, in mice, it seems that dysfunctional telomeres can initiate genomic instability at lengths that do not trigger checkpoints resulting in tumor suppression, or that a small number of dysfunctional telomeres can initiate instability and not trigger a checkpoint. However, the cell culture models suggest that this may not be the case in human cancer. The lack of a senescence checkpoint in late generation mouse The in¯ection point in the growth curve is only observed when cells are grown at low cell densities. Rather than stopping growth at a senescence point, mouse cells immortalize spontaneously mTR 7/7 cells indicates that mice may not respond to short telomeres during tumorigenesis with the same timing or severity as human cells. It may be that in humans, short telomeres trigger checkpoint arrest before they shorten to a point where they can initiate genetic instability. It will be interesting to determine whether telomere dysfunction can provide a primary initiating step in tumorigenesis, or whether it can only contribute to chromosomal instability in tumors after loss of a checkpoint. Perhaps triggering of a checkpoint can sometimes facilitate the fusion of dysfunctional telomeres by stimulating DNA repair pathways.
Telomerase activation facilitates tumor growth
Several lines of evidence suggest that activation of telomerase can facilitate tumor progression. The presence of telomerase activity in greater than 85% of cancers suggests that telomerase activity stimulates tumorigenesis by increasing cell proliferation (Kim et al., 1994; Shay and Bacchetti, 1997) . Typically, telomerase activation occurs late in tumorigenesis (Chadeneau et al., 1995; Tang et al., 1998) . Maintenance of telomere length is a common feature of tumors late in tumorigenesis; even in those tumors without detectable telomerase activity, telomere lengthening occurs through an alternative mechanism (ALT) (Bryan et al., 1997) . In mice, reintroduction of telomerase increases the tumor forming ability of late generation mTR 7/7 INK4a 7/7 ®broblast cultures. This reintroduction eliminates the signal-free ends in these cells, indicating that telomere function is restored (Greenberg et al., 1999) . In yeast, reintroduction of telomerase can eciently restore growth potential in cells with critically short telomeres, including cells with some degree of ongoing chromosomal instability (Hackett et al., 2001) . Thus in a number of systems telomerase activity can facilitate cell growth. However, in human cancer cells, where the checkpoints that recognize dysfunctional telomeres may have been inactivated, the exact role of telomerase activation is still not clear.
Telomerase inhibits genomic instability
In addition to the possible role of telomerase in preventing the initiation of chromosomal instability by maintaining telomere function, telomerase might also suppress mutagenic chromosome fusions that facilitate breakage-fusion-bridge (BFB) cycles by allowing telomere addition to repair broken ends. The role of telomerase in halting BFB cycles is supported by the work of Barbara McClintock. When a broken chromosome is transmitted to the endosperm in maize, BFB continues during the development of the endosperm. However, if a broken chromosome is transferred to the zygote, the broken end is healed and no BFB occurs (McClintock, 1941) . The presence of BFB in the endosperm, but not in the embryo may result from the presence of signi®cant telomerase activity in the embryo, but not in the endosperm (Killan et al., 1998) which allows telomerase to add a new telomere to broken ends in the embryo. Telomerase-mediated de novo telomere addition has been demonstrated as a mechanism for healing broken chromosomes in yeast (Kramer and Haber, 1993) . In support of the role of telomere addition in limiting BFB, yeast that undergo gross chromosomal rearrangements are more likely to contain chromosome fusions and rearrangements involving multiple chromosomes in the absence of telomerase than when telomerase is present (Hackett et al., 2001; Myung et al., 2001) . Despite a possible role for telomerase in limiting BFB, the signi®cance of a decrease in genetic instability following telomerase activation in the process of tumorigenesis is unclear. Interestingly, nonreciprocal translocations are clonally stable in p53 7/7 mTR 7/7
tumors (Artandi et al., 2000) . This suggests that stabilization of genomic instability can occur even in the absence of telomerase. In these cells telomere function may be restored though the ALT pathway. It remains possible that telomerase activation may be signi®cant for tumor growth simply by increasing the growth potential of cells with short telomeres rather than by limiting genomic instability. It is also possible that telomerase activation per se does not always confer a selective advantage, but is merely the byproduct of other changes in the tumor such as Myc activation. However, this explanation seems unlikely given the presence of either telomerase activity or the ALT mechanism in tumors.
Future directions
The apparently con¯icting eects of telomere dysfunction and telomerase activation in tumorigenesis can be understood in terms of the timing of these processes.
Telomere dysfunction probably contributes to relatively early stages of tumorigenesis ( Figure 3 ). It is not yet clear whether telomere dysfunction inhibits tumor growth before or after the initiation of genetic instability. Telomerase activation seems to occur late in tumorigenesis and may contribute to the growth potential of the tumor after genetic instability has been established ( Figure 3 ). Telomerase inhibitors have been proposed as chemotheraputic agents (Counter et al., 1992; Harley et al., 1990) and are currently being studied by pharmaceutical companies. Reintroduction of telomerase into tissues undergoing high turnover-rate due to disease has also been proposed as a possible tumor-suppressive therapy (DePinho, 2000) . The antagonistic nature of these two therapies reveals possible problems with attempting to target telomeres or telomerase to ®ght cancer. Telomerase inhibitors function by reducing telomeres to a critical length. While telomerase inhibition may decrease the growth of late stage tumors, it may also select for more malignant subclones from the tumors by enhancing genomic instability. Therefore, care should be taken when using these drugs. It may be that the risk of outgrowth of a resistant subclone could be minimized by combination therapy.
An important area of future research will be to establish how frequently short telomeres trigger genomic instability versus apoptosis during tumor initiation. Is there actually a link between telomere dysfunction and chromosomal instability in human tumors? Can dysfunctional telomeres initiate genomic instability in the absence of other mutations in checkpoint genes, or is the main role of telomere dysfunction in ongoing chromosomal instability after the loss of checkpoints?
The mechanism that mediates the fusion of dysfunctional telomeres are also largely unknown. Knowledge of this mechanism could suggest possible ways to minimize chromosome fusion and maximize apoptosis in response to dysfunctional telomeres. Such an approach would have the advantage of directly targeting dysfunctional telomeres, rather than altering telomerase expression. 
